Keywords: Takeda. Azilsartan, US, NDA, Hypertension, Nesina, Diabetes, Japan

Takeda files US NDA for combo hypertension drug; gets new indications for Nesina in Japan

Article | 25 February 2011

Print This

The US affiliate of Japan’s largest drugmaker, Takeda Pharmaceutical ((TSE: 4502), has submitted a New Drug Application to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in